# Recovery Peptide FAQ — BPC-157, TB-500, GHK-Cu, KPV — Sovereign Peptides

> Frequently asked questions about four Recovery & Tissue Repair research peptides — BPC-157, TB-500, GHK-Cu and KPV — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to these four recovery peptides.

## What does BPC-157 do in the body?

In animal models, BPC-157 is described as a cytoprotective (cell-protecting) and regenerative peptide. Its repair effects are tied most consistently to *angiogenesis* — encouraging the growth of new blood vessels into injured tissue by making blood-vessel cells more responsive to the VEGFR2 vessel-growth signal [4]. It has accelerated healing in rat models of gastric ulcers [5] and transected tendon [6], and it is also described as modulating brain-gut signaling pathways [7]. Crucially, almost all of this is preclinical; human evidence is limited to three small pilot studies [2].

## Is BPC-157 a growth hormone?

No. BPC-157 is not a growth hormone and is not growth hormone in any form. It is a synthetic fifteen-amino-acid peptide derived from a protein in gastric juice. There is a connection point that sometimes causes confusion: in tendon cells, BPC-157 has been reported to sensitize the *growth-hormone receptor*, which may amplify the effect of the body's own growth hormone [7]. Making a receptor more responsive is not the same as being a growth hormone. BPC-157 does not replace or act as growth hormone itself.

## Does BPC-157 work immediately, and how long does it stay in the body?

The peptide clears from the bloodstream quickly. Pharmacokinetic work in rats and dogs found a very short elimination half-life — under 30 minutes — with rapid breakdown into small fragments that re-enter normal amino-acid metabolism [3]. A short half-life means the intact peptide does not linger long after dosing. Whether any healing *effect* appears quickly is a separate question, and the published healing data are from animal studies measured over days to weeks, not immediate human outcomes [6]. This site does not advise on use or timing.

## Does BPC-157 damage the liver?

The available data do not show liver harm, but the data are very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic (liver), cardiac, renal, thyroid or glucose biomarkers and no adverse events [1]. That is reassuring but it is two people in a safety pilot, not a liver-safety study. The broader literature stresses that without long-term, large-sample human data, the overall safety profile remains genuinely unknown [2]. Nothing here is medical advice.

## What is TB-500, and what does the "TB" stand for?

"TB" refers to *thymosin beta* — specifically thymosin beta-4 (Tβ4), the natural protein TB-500 is derived from. TB-500 itself is a synthetic seven-amino-acid fragment, Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of that protein [12]. An important nuance: in commerce and anti-doping science, "TB-500" means the short fragment, but most published efficacy research uses the full-length Tβ4 protein, which is about five times larger [8]. So the name points at a fragment while much of its reputation rests on the whole protein.

## What is TB-500 used for in research?

In research, TB-500 (and, more often, full-length thymosin beta-4) is studied for tissue repair driven by actin regulation: cell migration, new blood-vessel growth, reduced scarring, and anti-inflammatory signaling, with models in dermal wounds, cornea, heart and CNS [10]. A human Phase 1 study of full-length Tβ4 in 40 volunteers focused on safety and pharmacokinetics rather than a specific disease [11], and a rat stroke study examined neurological recovery [9]. There are no completed controlled clinical trials of the TB-500 fragment itself for any indication [8].

## Does TB-500 work for muscle tears and recovery from exercise?

There is no controlled human evidence that the TB-500 fragment helps muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in cell migration and repair [10], but a 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury and athletic performance concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, and that these compounds operate largely outside regulatory oversight [8]. Notably, in a muscular-dystrophy mouse model chronic Tβ4 increased regenerating fibers but did *not* improve muscle strength [10]. TB-500 is also banned in sport [8].

## What does a GHK-Cu peptide do, and how does it work?

GHK-Cu is a copper-carrying tripeptide that does two things at once: it ferries copper into tissue and it signals repair. At very low concentrations it tells dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and decorin, while rebalancing matrix-degrading enzymes against their inhibitors; the copper itself enables collagen/elastin cross-linking and an antioxidant action [16]. At the gene level it shifts expression of roughly 31.2% of human genes (at a 50%-or-greater change threshold) toward repair, DNA-repair and antioxidant programs [14]. Most of its documented human benefit is in topical skin applications [13].

## Is GHK-Cu really anti-aging?

There is real, if modest and mostly topical, human evidence for skin benefits. Topical GHK-Cu increased collagen production in about 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison, and reviews document placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [16]. Two honest caveats belong with that: the dramatic "~4,000 genes" claim is an extrapolation from a verified figure of roughly 2,100 genes at the measured threshold [14], and the peptide penetrates intact skin poorly, which limits how much reaches the dermis without delivery aids [13]. Systemic "anti-aging" use is unproven.

## What is the difference between GHK and GHK-Cu?

GHK is the bare tripeptide glycyl-histidyl-lysine; GHK-Cu is that same tripeptide *chelated* to a copper(II) ion. The distinction is not cosmetic — copper coordination is required for most of GHK's reported bioactivities, so the form used in a given study genuinely matters, and the two are frequently conflated in secondary sources [16]. In practice, when research describes collagen stimulation, cross-linking and the antioxidant effects, it is generally the copper complex (GHK-Cu) doing the work.

## What is KPV peptide, and what is it used for?

KPV is a three-amino-acid peptide (Lys-Pro-Val) that is the C-terminal tail of the hormone alpha-MSH. In research it is used as an *anti-inflammatory* agent: it suppresses the NF-kB and MAP-kinase signaling that drives inflammation and lowers pro-inflammatory cytokines [20], while lacking the pigment-producing effect of the full hormone [22]. Its most-studied application is models of gut inflammation (colitis in mice), where it has reduced disease severity and accelerated mucosal healing [21][19]. There are no human clinical trials of KPV [20].

## What is KPV peptide good for, according to the research?

The research signal is strongest for *calming inflammation*, especially in the gut. KPV reduced colonic inflammation, sped recovery and lowered inflammatory markers in mouse colitis [21], and targeted-delivery formulations carrying KPV to inflamed colon tissue outperformed non-targeted versions [19][18]. A broad review also notes anti-inflammatory and protective effects of alpha-MSH-derived tripeptides across many models — skin, eye, airway, joints and more [22]. All of this is preclinical; KPV is not an approved treatment for any condition, and this site gives no dosing or medical advice [20].

---

A cross-referenced reading desk for recovery-peptide research — citations, not prescriptions, and never a product for sale.